Daily Stock Analysis, ASMB, Assembly Biosciences Inc, priceseries

Assembly Biosciences Inc. Daily Stock Analysis
Stock Information
Open
14.66
Close
16.60
High
17.19
Low
14.52
Previous Close
14.57
Daily Price Gain
2.03
YTD High
17.19
YTD High Date
Jan 17, 2017
YTD Low
11.85
YTD Low Date
Jan 3, 2017
YTD Price Change
4.41
YTD Gain
36.18%
52 Week High
17.19
52 Week High Date
Jan 17, 2017
52 Week Low
4.33
52 Week Low Date
Mar 1, 2016
52 Week Price Change
11.00
52 Week Gain
196.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2015
8.65
Mar 11. 2015
14.28
25 Trading Days
65.14%
Link
LONG
Apr 7. 2015
15.09
Apr 22. 2015
18.16
11 Trading Days
20.31%
Link
LONG
May 20. 2015
14.31
Jun 10. 2015
16.89
14 Trading Days
18.06%
Link
LONG
Jun 25. 2015
17.01
Jul 7. 2015
18.27
7 Trading Days
7.40%
Link
LONG
Sep 16. 2015
13.78
Sep 21. 2015
14.61
3 Trading Days
6.02%
Link
LONG
Oct 28. 2015
10.14
Oct 29. 2015
10.69
1 Trading Days
5.37%
Link
LONG
Aug 16. 2016
5.90
Aug 31. 2016
6.22
11 Trading Days
5.39%
Link
LONG
Oct 4. 2016
7.69
Nov 2. 2016
13.05
21 Trading Days
69.67%
Link
Company Information
Stock Symbol
ASMB
Exchange
NasdaqCM
Company URL
http://www.assemblybio.com
Company Phone
(212) 554-4388
CEO
Derek A. Small
Headquarters
New York
Business Address
99 HUDSON STREET, 5TH FLOOR, NEW YORK, NY 10013
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001426800
About

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and to restore health to a dysbiotic microbiome in the United States.

Description

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead drug candidate from the platform is AB-M101, is in development for the treatment of C. difficile- infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.